R&D Spending Increases Exponentially for Higher Standard of Breast Cancer Drug Treatments
The R&D spending from companies like Johnson & Johnson Services, Inc.; Merck & Co., Inc.; Celgene Corporation; Pfizer, Inc.; GlaxoSmithKline plc; Sanofi; and AbbVie, Inc. has increased exponentially.
- The R&D spending from companies like Johnson & Johnson Services, Inc.; Merck & Co., Inc.; Celgene Corporation; Pfizer, Inc.; GlaxoSmithKline plc; Sanofi; and AbbVie, Inc. has increased exponentially.
- Early detection of breast cancer is a key to effective management of the disease.
- HER2 inhibitors is identified as the most lucrative segment of the breast cancer drugs market.
- Growing incidence of HER2 positive breast cancer is the major factor attributed to the growth of this segment.